153 related articles for article (PubMed ID: 9093710)
1. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?
Hernberg M; Muhonen T; Pyrhönen S
Ann Oncol; 1997 Jan; 8(1):71-7. PubMed ID: 9093710
[TBL] [Abstract][Full Text] [Related]
2. Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
Bergerat JP; Ford J; Herbrecht R; Dufour P; Oberling F; Jacqmin D; Bollack C; Prevot G; Salze P; Jurascheck F
Prog Clin Biol Res; 1990; 348():137-50. PubMed ID: 2385604
[No Abstract] [Full Text] [Related]
3. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
5. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
6. Interferon update.
Pyrhönen S
Urologe A; 2004 Sep; 43 Suppl 3():S137-8. PubMed ID: 15148576
[No Abstract] [Full Text] [Related]
7. Prognostic histological and immune markers of renal cell carcinoma.
Magyarlaki T; Buzogány I; Kaiser L; Sükösd F; Döbrönte R; Simon B; Fazekas A; Nagy J
Pathol Oncol Res; 2001; 7(2):118-24. PubMed ID: 11458274
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
Kriegmair M; Oberneder R; Hofstetter A
Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
[TBL] [Abstract][Full Text] [Related]
9. [Interferon and vinblastine in presumably operable metastases of renal carcinoma].
Pizzocaro G; Piva L; Faustini M; Mangiarotti B; Nicolai N; Salvioni R; Milani A; Zanoni F
Arch Ital Urol Androl; 1993 Apr; 65(2):177-80. PubMed ID: 8330064
[TBL] [Abstract][Full Text] [Related]
10. [Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma].
Arima K; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J; Saitoh K; Yamazaki Y; Mori O; Oomoto Y; Nakagawa M
Hinyokika Kiyo; 1994 Jun; 40(6):469-74. PubMed ID: 8073952
[TBL] [Abstract][Full Text] [Related]
11. Immune reactive proteins in renal cell carcinoma patients treated by IFN alpha alone or in combination with vinblastine.
Juranić Z; Stanojević-Bakić N; Maletić V; Borkovacki R
Neoplasma; 1994; 41(4):229-32. PubMed ID: 7935998
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
Göhring B; Riemann D; Rebmann U; Heynemann H; Schabel J; Langner J
Urol Res; 1996; 24(5):297-303. PubMed ID: 8931295
[TBL] [Abstract][Full Text] [Related]
14. Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma.
Schmidinger M; Steger GG; Budinsky AC; Wenzel C; Brodowicz T; Locker GJ; Kramer G; Marberger M; Zielinski CC
Anticancer Drugs; 2000 Mar; 11(3):175-9. PubMed ID: 10831276
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
[TBL] [Abstract][Full Text] [Related]
16. T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine.
Gez E; Mekori T; Struminger L; Rubinov R; Nativ O; Stein A; Haim N; Kuten A
Cancer Invest; 1999; 17(4):259-63. PubMed ID: 10225005
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma.
Characiejus D; Pasukoniene V; Kazlauskaite N; Valuckas KP; Petraitis T; Mauricas M; Den Otter W
Anticancer Res; 2002; 22(6B):3679-83. PubMed ID: 12552976
[TBL] [Abstract][Full Text] [Related]
18. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of TILs in renal cell carcinoma.
Yogi S; Onodera Y; Ikeuchi T; Matsumoto K; Kai Y
Int J Urol; 1996 Jan; 3(1 Suppl):S22-3. PubMed ID: 24304014
[No Abstract] [Full Text] [Related]
20. [Immunotherapy in the management of metastatic renal carcinoma].
Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
